Roche’s Tecentriq immunotherapy for SCLC treatment approved by USDFA
Category: #health  By Paroma Bhattacharya  Date: 2019-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche’s Tecentriq immunotherapy for SCLC treatment approved by USDFA

The US FDA (Food & Drug Administration) has reportedly granted approval for Swiss drug-maker Roche Holding’s immunotherapy Tecentriq intended for treating ES-SCLC (Extensive Stage-Small Cell Lung Cancer). Reportedly, this is the latest win for the drug, the sales of which trail medicines from Bristol-Myers Squibb and Merck & Co.

The US regulator’s latest move comes along the heels of a recent Phase 3 Impower133 study showing that Tecentriq combined with chemotherapy (etoposide and carboplatin) appreciably helped patients live longer (a median 12.3 months) in comparison to chemotherapy alone (a median 10.3 months). Sources familiar with the development stated that around 10 to 15 per cent of lung cancers are small cell cancers, due to which tumors tend to spread at an early stage. However, the SCLC treatments are advancing gradually and Roche’s Tecentriq has been hailed as the first potential option discovered in over two decades.

Sandra Horning, Chief Medical Officer, Head of Global Product Development, Roche Holding, was reported saying that Tecentriq is the first cancer immunotherapy that has been accepted for the initial treatment of ES-SCLC, which is a difficult-to-treat cancer type. Horning further added that there has been limited progress in the treatment of this disease so far, and the company is excited to be introducing a new standard of care for patients that holds more potential to improve survival.

Reportedly, the Phase 3 Impower133 study is multi-center, randomised placebo-controlled and double-blinded, which assesses the safety and efficiency of Tecentriq, in conjunction with chemotherapy. The study had enrolled around 403 patients who were equally randomised to receive Tecentriq combined with carboplatin & etoposide in Arm A, and then placebo combined with the same in Arm B and control Arm. The co-primary endpoints were PFS (progression-free survival) as established by the investigator. 

Authentic reports further mentioned that Tecentriq received $766 million in revenue in 2018, while Bristol- Myers’ Opdivo and Merck’s Keytruda immunotherapy gained $6.7 billion and $7.2 billion respectively in the same year.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...

ViiV Healthcare announces positive result in TANGO Phase 3 study
ViiV Healthcare announces positive result in TANGO Phase 3 study
By Paroma Bhattacharya

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess vira...

Skyhawk Therapeutics expands licensing partnership with Biogen
Skyhawk Therapeutics expands licensing partnership with Biogen
By Paroma Bhattacharya

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyh...